Foulc P, Evrard V, Dalac S, Guillot B, Delaunay M, Verret J-L, Dréno B
Department of Dermatology, CHU Nantes, 1 place Alexis Ricordeau, 44035 Nantes cedex 1, France.
Br J Dermatol. 2002 Nov;147(5):926-30. doi: 10.1046/j.1365-2133.2002.04802.x.
Mechlorethamine is frequently used in the treatment of cutaneous lymphoma, but its application is limited in 30-80% of cases because of cutaneous intolerance. Reducing the concentration to avoid this side-effect has been only modestly successful.
To investigate whether a shorter application period could reduce the frequency of intolerance.
In an open prospective study in 39 patients with cutaneous T-cell lymphoma or parapsoriasis, mechlorethamine was applied according to the usual practices of the participating physicians (number of weekly applications, treatment confined to lesions or performed over the entire body) and then washed off after 1 h in all cases.
Cutaneous intolerance was observed in 19 of 39 patients (49%). Six of these patients showed allergic contact dermatitis to mechlorethamine after a mean period of 9.3 weeks, while the other 13 developed irritant contact dermatitis after a longer period. Cutaneous intolerance did not differ significantly according to the number of applications per week or the extent of body area treated. The therapeutic response rate was 69%, and no difference in therapeutic efficacy was noted between daily and intermittent applications.
Comparison with published studies showed no significant difference in the number of cases of cutaneous intolerance after short-term application, although their occurrence was delayed. Therapeutic response was decreased appreciably by short-term application as compared with results in the literature.
氮芥常用于皮肤淋巴瘤的治疗,但由于皮肤不耐受,其应用在30%至80%的病例中受到限制。降低浓度以避免这种副作用仅取得了一定程度的成功。
研究缩短用药时间是否能降低不耐受的发生率。
在一项针对39例皮肤T细胞淋巴瘤或副银屑病患者的开放性前瞻性研究中,氮芥按照参与研究的医生的常规做法使用(每周用药次数、治疗局限于皮损部位或全身用药),所有病例用药1小时后冲洗掉。
39例患者中有19例(49%)出现皮肤不耐受。其中6例患者在平均9.3周后出现对氮芥的过敏性接触性皮炎,另外13例在更长时间后出现刺激性接触性皮炎。皮肤不耐受在每周用药次数或治疗的身体面积范围方面无显著差异。治疗有效率为69%,每日用药和间歇用药之间的治疗效果无差异。
与已发表的研究相比,短期用药后皮肤不耐受的病例数无显著差异,尽管其发生有所延迟。与文献报道的结果相比,短期用药明显降低了治疗反应。